Koers Brainstorm Cell Therapeutics Inc OTC Bulletin Board
Aandelen
US10501E2019
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 38,75 mln. 35,69 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -21 mln. -19,34 mln. | Nettowinst (verlies) 2025 * | -27 mln. -24,86 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,03
x | K/w-verhouding 2025 * |
-1,51
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,71% |
Recentste transcriptie over Brainstorm Cell Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chaim Lebovits
CEO | Chief Executive Officer | 53 | 01-07-07 |
Alla Patlis
DFI | Director of Finance/CFO | 37 | 23-12-12 |
Chief Tech/Sci/R&D Officer | - | 12-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Irit Arbel
FOU | Founder | 64 | 22-09-00 |
Uri Yablonka
BRD | Director/Board Member | 47 | 06-06-14 |
Jacob Frenkel
CHM | Chairman | 81 | 30-03-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,79% | 54,04 mld. | |
-0,56% | 41,92 mld. | |
+49,62% | 41,96 mld. | |
-7,20% | 28,35 mld. | |
+12,59% | 26,35 mld. | |
-21,51% | 19 mld. | |
+6,92% | 13 mld. | |
+24,91% | 12,19 mld. | |
+29,60% | 12,28 mld. |
- Beurs
- Aandelen
- Koers BCLI
- Koers